ArticleNature reviews. Gastroenterology & hepatology2022
Nomenclature of HBV core protein-targeting antivirals.
Abstract read
In one paragraph
Article in Nature reviews. Gastroenterology & hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- First-in-human study on the pharmacokinetics, safety, and tolerability of single escalating doses and multiple doses of XT1061, a novel core protein allosteric modulator, in healthy Chinese subjects.Frontiers in pharmacology · 2026Trial
- Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled design.Virology journal · 2024Trial
- Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients.Clinical and molecular hepatology · 2024Trial
- Trial
- A New Role of Class A Hepatitis B Virus Capsid Assembly Modulators in Core Protein Dynamics and Covalently Closed Circular DNA Replenishment.Cellular and molecular gastroenterology and hepatology · 2026Article
- Negative cooperativity drives activity of capsid-directed antivirals against hepatitis B virus.Science advances · 2026Article
- Free-Energy Landscapes of HBV Hexamer Closure Reveal Key Structural Features of the Transition.Journal of chemical theory and computation · 2026Article
- Assembly-active and -inactive forms of HBV capsid protein provide distinctly different binding sites for capsid assembly modulators.bioRxiv : the preprint server for biology · 2026Article
- Cryo-EM structures of HBV capsids from human cells at near-atomic resolution.Structure (London, England : 1993) · 2026Article
- Combination therapies for chronic hepatitis B in the era of emerging novel drugs.Hepatology international · 2026Review
- Mechanistic insights into CAM-induced disruption of HBV capsids revealed by all-atom MD simulations.PLoS pathogens · 2026Article
- Functional immune responses induced by a capsid assembly modulator in chronic hepatitis B virus-infected humanized mice.Cell host & microbe · 2026Article
- Hepatitis B Virus Nucleocapsid Assembly.Journal of molecular biology · 2025Review
- Discovery ofInternational journal of molecular sciences · 2025Article
- HBV p22-interacting protein C1QBP inhibits viral replication through impeding nucleocapsid formation and nuclear import.PLoS pathogens · 2025Article
- Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study.JHEP reports : innovation in hepatology · 2025Article
- Mechanistic insights into CAM-induced disruption of HBV capsids revealed by all-atom MD simulations.bioRxiv : the preprint server for biology · 2025Article
- HBV capsid assembly modulators differentially modulate the assembly of wild-type and drug-resistant core protein chimeric nucleocapsids and empty capsids.PLoS pathogens · 2025Article
- Discovery of VNRX-9945, a Potent, Broadly Active Capsid Assembly Modulator as a Clinical Candidate for the Treatment of Chronic Hepatitis B Virus Infection.ACS medicinal chemistry letters · 2025Article
- PGLYRP2 drives hepatocyte-intrinsic innate immunity by trapping and clearing hepatitis B virus.The Journal of clinical investigation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Fabien Zoulim *Hepatology Department, INSERM Unit 1052, Hospices Civils de Lyon, Lyon University, Lyon, France. fabien.zoulim@inserm.fr.ORCID 0000-0002-2245-0083
Adam Zlotnick *Molecular and Cellular Biochemistry Department, Indiana University, Bloomington, IN, USA.ORCID 0000-0001-9945-6267
Stephanie BuchholzFederal Institute for Drugs and Medical Devices, BfArM, Bonn, Germany.
Eric DonaldsonUS Food and Drug Administration, Silver Spring, MD, USA.
John FryAligos Therapeutics, San Francisco, CA, USA.
Anuj GaggarArrive Bio, San Francisco, CA, USA.
Jianming HuDepartment of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, PA, USA.
Michael KannDepartment of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Oliver LenzJanssen Pharmaceutica NV, Beerse, Belgium.
Kai LinAerium Therapeutics, Boston, MA, USA.ORCID 0000-0003-2186-7466
Nagraj ManiArbutus Biopharma Inc., Department of Biology, Warminster, PA, USA.ORCID 0000-0002-8446-2338
Michael NassalDepartment of Medicine II, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
William DelaneyAssembly Biosciences, South San Francisco, CA, USA.
Su WangCooperman Barnabas Medical Center, RWJBarnabas-Rutgers Medical Group, Livingston, NJ, USA.
Gabriel WestmanSwedish Medical Products Agency, Uppsala University, Uppsala, Sweden.
Veronica MillerThe Forum for Collaborative Research, Washington, DC, USA.
Harry L A JanssenDepartment of Gastroenterology & Hepatology, Erasmus Medical Center, Rotterdam, Netherlands.
Funding
MECHANISMS OF HEPADNAVIRUS ASSEMBLY AND REPLICATIONR01AI043453 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI HU, JIANMING · 1999 to 2017
$5.9MMultimode Observation of Virus Capsid AssemblyR01AI118933 · NIAID · TRUSTEES OF INDIANA UNIVERSITY · PI Adam Zlotnick · 2016 to 2026
$4.0MMechanisms of Hepadnavirus Assembly and ReplicationR37AI043453 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI Jianming Hu · 2018 to 2026
$3.8MThe Structural Biology of HBVR01AI144022 · NIAID · TRUSTEES OF INDIANA UNIVERSITY · PI ZLOTNICK, ADAM · 2019 to 2022
$1.5MNIAID NIH HHS R01 AI043453NIAID NIH HHS R01 AI118933NIAID NIH HHS R01 AI144022NIAID NIH HHS R37 AI043453
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antiviral AgentsHepatitis B virusDNA, ViralHumansVirus ReplicationAntiviral AgentsDNA, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.